Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

US FDA Might Face Funding Penalty For Missing User Fee Goals

Executive Summary

Industry representatives support adding a provision to the user fee agreements that would withdraw some taxpayer funding if the agency does not meet its deliverables.

Advertisement

Related Content

FDA Faces Budget Crunch In 2023 Under User Fee Legislation
US FDA Faces Hiring Slowdown, Funding Cuts In Trump's FY 17 Plan
User Fees: Should US FDA Incur Penalties For Missed Deadlines?
The Freeze Thaws: US FDA Allowed To Hire Staff For Cures, User Fee Activity
FDA User Fee Hearing Hijacked By US Health Care Reform Arguments
Trump's Budget Outline Threatens User Fee Agreements
Generic Drug First-Cycle Approval Rates Lagging Under GDUFA I
FDA Met Biosimilar Review Timelines But Missed Meeting Goals In 2015
Biosimilar User Fee Talks Begin With Industry Negotiating Amongst Itself
Abuse-Deterrent Opioids Could Gain Significant First-Mover Advantage Under FDA Guidance

Topics

Advertisement
UsernamePublicRestriction

Register

PS120371

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel